B
efore the pandemic, AstraZeneca was highly regarded in the business and pharmaceutical world – seen as one of the UK’s best companies. Now, thanks to Britain’s successful vaccine programme, it is a household name.
B
efore the pandemic, AstraZeneca was highly regarded in the business and pharmaceutical world – seen as one of the UK’s best companies. Now, thanks to Britain’s successful vaccine programme, it is a household name.

When a child is seriously sick or injured, an entire lifetime hangs in the balance. Yet, nationally, funding for pediatric research continues to trail efforts targeted for adults. Children deserve innovation inspired by their needs.
That’s why Children’s National Hospital is creating a one-of-a-kind pediatric research and innovation hub. Located on a nearly 12-acre portion of the former Walter Reed Army Medical Center campus, we will combine our strengths with those of public and private partners who share our vision. Here, breakthrough discoveries can more quickly be translated into new treatments and technologies benefitting kids.
Virginia Tech Corporate Research Center President and CEO, Brett Malone, Ph.D., joins Rich Bendis on BioTalk to discuss regional expansion plans, strategic partnerships, and success stories.
Listen now via Apple http://apple.co/3cPyW3t, Google http://bit.ly/3a1kP9m, Spotify http://spoti.fi/3cSwQ2Q, and TuneIn http://bit.ly/3a1kYJW

The Maryland Business Innovation Association (MBIA) has partnered with the Maryland Department of Commerce to launch the inaugural Maryland Business Innovation Challenge, which will aim to break down barriers and create opportunities for collaboration between Maryland’s corporate and innovation communities.
Betsy O’Neill Collie, senior director of operations and programming for MBIA, said the challenge is aimed at companies looking to “to tap into the kinds of brilliance we have in Maryland.” As opposed to other kinds of challenges, such as startup pitch competitions, O’Neill Collie said this will offer the chance for more direct business collaborations.

THE BIDEN administration announced Monday that it is investing $230 million in Ellume, an Australian company, for millions of its at-home coronavirus testing kits.
The deal, struck by the Department of Health and Human Services and the Department of Defense, ensures 100,000 over-the-counter test kits will arrive in the U.S. starting this month through July, acting Centers of Medicare and Medicaid Services Administrator Andy Slavitt said Monday during a White House briefing.
Medical device engineering firm, Engenious Design, partners with Innara Health to design the 2nd generation of their ground-breaking technology designed to improve feeding outcomes in premature infants. Prairie Village, KS: Engenious Design, a 39-person creative product development firm specializing in electronic medical device design, has partnered with Kansas City-based start-up Innara Health to develop Innara’s next-generation NTrainer System ®, designed to improve access to more patients by reducing the size and cost of the system, enabling Innara to expand into new markets and provide better access to life-changing therapy and assessment tools for infants.

The Children’s National Research & Innovation Campus (RIC), the first-of-its-kind pediatric research and innovation hub located in Washington, D.C., now has its first occupant – the Rare Disease Institute (RDI).
The institute, which includes the largest clinical group of pediatric geneticists in the nation, focuses on developing the clinical care field of the more than 8,000 rare diseases currently recognized and advancing the best possible treatments for children with these diseases.
Image: https://innovationdistrict.childrensnational.org/

The COVID-19 pandemic is a stark wake-up call for the United States to take biological threats seriously. The virus is on track to take the lives of more than 400,000 Americans and cost our economy trillions of dollars. The risks of future pandemics increase as technological progress eases barriers to modifying pathogens, raising the specter of novel biological agents causing diseases much worse than humanity has ever faced. Meanwhile, U.S. vulnerabilities to biological attacks have never been clearer to our adversaries.
However, there is a path forward. The Apollo Program for Biodefense would provide the United States the opportunity to mobilize the nation and lead the world to meet these challenges: a world where we detect and continually trace any new pathogen from the source; where we can distribute rapid point-of-person tests to every household in the country within days of that detection; where effective treatments are already in-hand; where vaccine development and rollout occur in weeks rather than years; and where pandemics will never again threaten the lives and livelihoods of Americans and people around the world.

Two young pharmaceutical companies are teaming up to bring a sizable new facility and nearly 200 new jobs to Petersburg.
Gov. Ralph Northam announced Thursday that Civica Inc., a Utah-based drug manufacturing nonprofit, will build a $124.5 million pharmaceutical plant along North Normandy Drive in Petersburg.
Image: The proposed $125 million pharmaceutical plant in Petersburg will total 120,000 square feet. (Courtesy of Phlow)

The move comes less than three years after the Gaithersburg biotech spun out of MedImmune.
Image: Viela Bio CEO Bing Yao, pictured here on the company’s IPO day at the Nasdaq. LIBBY GREENE